NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
551 Örebro

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 100 3.0% 33 1.0% 5 0.1% 1 0.0% . . 15 0.4% 3190 95.4% 3344 100.0%
ASCUS 241 22.8% 174 16.5% 55 5.2% 4 0.4% . . 69 6.5% 514 48.6% 1057 100.0%
LSIL 151 15.9% 206 21.6% 140 14.7% 1 0.1% . . 56 5.9% 398 41.8% 952 100.0%
Atypical glandular cells/AGC 5 18.5% 1 3.7% 1 3.7% 7 25.9% 2 7.4% . . 11 40.7% 27 100.0%
Unclear atypia 15 30.6% 5 10.2% 12 24.5% 2 4.1% 1 2.0% 3 6.1% 11 22.4% 49 100.0%
ASC-H 2 28.6% . . 5 71.4% . . . . . . . . 7 100.0%
HSIL 13 4.6% 24 8.5% 214 75.6% 5 1.8% 4 1.4% 10 3.5% 13 4.6% 283 100.0%
Suspected Adenocarcinom . . . . . . . . . . . . 4 100.0% 4 100.0%
Malignant tumor with unclear origin . . . . . . . . . . . . 2 100.0% 2 100.0%
Squamous cell cancer . . . . 1 50.0% . . . . . . 1 50.0% 2 100.0%
Totalt 527 9.2% 443 7.7% 433 7.6% 20 0.3% 7 0.1% 153 2.7% 4144 72.4% 5727 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M81403